^
Association details:
| Biomarker: | B2M rs1901531 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genetic variations in the ß2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial
Published date:
05/16/2018
Excerpt:
β2Mrs1901531 mutant C allele carriers showed improved OS (67.4 vs 40.9 mo) independent of RAS status in FOLFIRI/cet arm in both univariate (HR = 0.27; 95%CI = 0.12-0.59; p < 0.001) and multivariable analysis (HR = 0.19; 95%CI = 0.07-0.48; p < 0.001).
Secondary therapy:
FOLFIRI
DOI:
10.1200/JCO.2018.36.15_suppl.12107
Trial ID:
